10817
Apolipoprotein A-I from human plasma
≥90% (GE)
Synonym(s):
Apo A-1
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
human plasma
Assay
≥90% (GE)
form
lyophilized solid
mol wt
Mr ~28300
solubility
H2O: 1 mg/mL, clear, colorless
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
Gene Information
human ... APOA1(335)
Looking for similar products? Visit Product Comparison Guide
General description
Apolipoprotein A-I (apoA-I) is the chief protein component of high density lipoproteins (HDL) and a major determinant of HDL structure, composition, and stability. It is an exchangeable apolipoprotein and plays pivotal role in the metabolism of cholesterol.
Application
Apolipoprotein A-I (apoA-I) was used for protecting the heart against vascular disease, it also protects other vascular beds and organs. It was protective against atherosclerosis through its ability to intervene in reverse cholesterol transport.
Biochem/physiol Actions
High-density lipoproteins are antiatherogenic and cardioprotective by facilitating reverse cholesterol transport (RCT). Some strategies for elevating apolipoprotein A-I levels are studied as therapies for atherosclerosis.
Preparation Note
lyophilized from 0.01 M ammonium hydrogen carbonate
Other Notes
A principal protein component of high-density lipoproteins. Protein - lipid interactions
Storage Class Code
13 - Non Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
R.B. Gennis et al.
Annual Review of Biophysics and Biophysical Chemistry, 6, 195-195 (1977)
Scott M Gordon et al.
Current opinion in endocrinology, diabetes, and obesity, 19(2), 109-114 (2012-01-27)
To review recently published advances in the development of apolipoprotein A-I (apoA-I) mimetic peptides as a potential treatment for cardiovascular diseases. Various apoA-I mimetic peptides are currently in development and these display potent cardioprotective features that can rival or even
Jens O Lagerstedt et al.
Biochimica et biophysica acta, 1821(3), 448-455 (2012-01-17)
Apolipoprotein A-I (apoA-I) is the major protein component of high density lipoproteins (HDL) and plays a central role in cholesterol metabolism. The lipid-free/lipid-poor form of apoA-I is the preferred substrate for the ATP-binding cassette transporter A1 (ABCA1). The interaction of
Weiling Wang et al.
Journal of lipid research, 51(9), 2560-2570 (2010-05-26)
The relationship between high-density lipoprotein and pulmonary function is unclear. To determine mechanistic relationships we investigated the effects of genetic deletion of apolipoprotein A-I (apoA-I) on plasma lipids, paraoxonase (PON1), pro-inflammatory HDL (p-HDL), vasodilatation, airway hyperresponsiveness and pulmonary oxidative stress
Ryan J Henderson et al.
Lipids in health and disease, 8, 27-27 (2009-07-25)
Haptoglobin is a plasma protein that scavenges haemoglobin during haemolysis. Phospholipid Transfer Protein (PLTP) transfers lipids from Low Density Lipoproteins (LDL) to High Density Lipoproteins (HDL). PLTP is involved in the pathogenesis of atherosclerosis which causes coronary artery disease, the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service